




RealRate

# PHARMACEUTICAL 2021

Sio Gene Therapies Inc.  
Rank 318 of 409



RealRate

• Financial Strength Rankings using Artificial Intelligence

• [www.realrate.ai](http://www.realrate.ai)



# PHARMACEUTICAL 2021

Sio Gene Therapies Inc.  
Rank 318 of 409

The relative strengths and weaknesses of Sio Gene Therapies Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Sio Gene Therapies Inc. compared to the market average is the variable Cost of Goods Sold, increasing the Economic Capital Ratio by 19% points. The greatest weakness of Sio Gene Therapies Inc. is the variable Net Income, reducing the Economic Capital Ratio by 199% points.

The company's Economic Capital Ratio, given in the ranking table, is -364%, being 9.5% points below the market average of -355%.

Input Variable	Value in 1000 USD
Assets, Current	85,430
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	32,043
Liabilities, Non-Current	79
Other Assets	7,449
Other Compr. Net Income	-966
Other Expenses	4,815
Other Liabilities	0
Other Net Income	1,358
Property and Equipment	801
Research and Development	47,110
Revenues	0
Selling, General and Administrative Expense	22,061

Output Variable	Value in 1000 USD
Assets	93,680
Liabilities	32,122
Expenses	73,986
Stockholders Equity	61,558
Net Income	-72,628
Comprehensive Net Income	-73,111
Economic Capital Ratio	-364%

